ArticlePloS one2023

A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer's disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial.

David S Henry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.